Romain BUISSON/LinkedIn
Nov 5, 2025, 05:14
Penumbra Announces Secondary Results of the Ground-Breaking STORM – PE RCT
Romain Buisson, Country Manager (TH-HK cluster) at Penumbra, Inc., shared a post by Penumbra, Inc. on LinkedIn:
”Latest updates in STORM PE
Patient treated with CAVT plus anticoagulation experienced significantly longer distance walked during the 90-day six-minute walk test (472m vs 376m; P = 0.019).
CAVT patients near normalized by 90 days, walking 94% of their predicted walk distance vs 75% in the anticoagulation only arm (P = 0.022)”
Quoting Penumbra, Inc.’s post:
”Penumbra announces secondary results of the ground-breaking STORM-PE RCT at VIVA 2025. Read more here.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?